Germany's drugs regulator has approved GW Pharma's Sativex cannabis-based medicine to treat muscle stiffness in multiple sclerosis patients - a significant step in one of Europe's largest medicine markets. GW will launch Sativex in Germany through its marketing partner Almirall in July 2011.
IC TIP:
Buy
at
125p
What we said: Buy
When: 10 Sep 2010
Price: 93p
Share tip performance to date: +34 per cent
